Novel Effect of Mineralocorticoid Receptor Antagonism to Reduce Proinflammatory Cytokines and Hypothalamic Activation in Rats With Ischemia-Induced Heart Failure
Tóm tắt
Blocking brain mineralocorticoid receptors (MRs) reduces the high circulating levels of tumor necrosis factor (TNF)-α in heart failure (HF) rats. TNF-α and other proinflammatory cytokines activate neurons in the paraventricular nucleus (PVN) of hypothalamus, including corticotropin-releasing hormone (CRH) neurons, by inducing cyclooxygenase (COX)-2 activity and synthesis of prostaglandin E 2 by perivascular cells of the cerebral vasculature. We tested the hypothesis that systemic treatment with a MR antagonist would reduce hypothalamic COX-2 expression and PVN neuronal activation in HF rats. Rats underwent coronary ligation to induce HF, confirmed by echocardiography, or sham surgery, followed by 6 weeks treatment with eplerenone (30 mg/kg per day, orally) or vehicle (drinking water). Eplerenone-treated HF rats had lower plasma TNF-α, interleukin (IL)-1β and IL-6, less COX-2 staining of small blood vessels penetrating PVN, fewer PVN neurons expressing Fra-like activity (indicating chronic neuronal activation), and fewer PVN neurons staining for TNF-α, IL-1β, and CRH than vehicle-treated HF rats. COX-2 and CRH protein expression in hypothalamus were 1.7- and 1.9-fold higher, respectively, in HF+vehicle versus sham+vehicle rats; these increases were attenuated (26% and 25%, respectively) in HF+eplerenone rats. Eplerenone-treated HF rats had less prostaglandin E 2 in cerebrospinal fluid, lower plasma norepinephrine levels, lower left ventricular end-diastolic pressure, and lower right ventricle/body weight and lung/body weight ratios, but no improvement in left ventricular function. Treatment of HF rats with anticytokine agents, etanercept or pentoxifylline, produced very similar results. This study reveals a previously unrecognized effect of MR antagonism to minimize cytokine-induced central neural excitation in rats with HF.
Từ khóa
Tài liệu tham khảo
Brown MR, Fisher LA. Corticotropin-releasing factor: effects on the autonomic nervous system and visceral systems. Fed Proc. 1985; 44: 243–248.
De Nicola AF, Grillo C, Gonzalez S. Physiological, biochemical and molecular mechanisms of salt appetite control by mineralocorticoid action in brain. Braz J Med Biol Res. 1992; 25: 1153–1162.
Fisher LA. Central actions of corticotropin-releasing factor on autonomic nervous activity and cardiovascular functioning. Ciba Found Symp. 1993; 172: 243–253.
Kang Y-M, Zhou R, Zheng W, Tomanek R, Felder RB. Pre-treatment with etanercept inhibits full expression of the pro-inflammatory cytokine cascade following acute myocardial infarction. FASEB J. 2005; 19: A1289 Abstract.
Voisin L, Breuille D, Ruot B, Ralliere C, Rambourdin F, Dalle M, Obled C. Cytokine modulation by PX differently affects specific acute phase proteins during sepsis in rats. Am J Physiol. 1998; 275: R1412–R1419.